|
WO2021037221A1
|
|
Nef-containing t cells and methods of producing thereof
|
|
WO2021008610A1
|
|
Anti-dll3 chimeric antigen receptors and uses thereof
|
|
WO2020228824A1
|
|
Immune cell receptors comprsing cd4 binding moieties
|
|
WO2020216238A1
|
|
Engineered cells and uses thereof
|
|
WO2020147708A1
|
|
Chimeric receptor polypeptides and uses thereof
|
|
WO2020140973A1
|
|
Modified immune cells expressing flagellin polypeptide
|
|
WO2020135559A1
|
|
Cd30-binding moieties, chimeric antigen receptors, and uses thereof
|
|
AU2019337759A1
|
|
Single-domain antibodies against CD33 and constructs thereof
|
|
SG11202101773WA
|
|
Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof
|
|
CA3103337A1
|
|
Nef-containing t cells and methods of producing thereof
|
|
TW202019954A
|
|
Co-receptor systems for treating infectious diseases
|
|
AU2019291627A1
|
|
Engineered cells and uses thereof
|
|
KR20200138720A
|
|
Single-domain antibodies to LAG-3 and uses thereof
|
|
CN111629754A
|
|
anti-CD 47 antibodies that do not cause significant red blood cell agglutination
|
|
CA3084518A1
|
|
Single-domain antibodies and variants thereof against pd-1
|
|
CN111601826A
|
|
Antibodies to TIGIT and variants thereof
|
|
KR20200118423A
|
|
Multispecific antigen binding proteins and methods of use thereof
|
|
SG11202005273XA
|
|
Antibodies and variants thereof against pd-l1
|
|
TW201930358A
|
|
Single-domain antibodies and variants thereof against TIGIT
|
|
WO2019105373A1
|
|
RECOMBINANT CELL FOR EVALUATING BIOACTIVITY OF ANTI-TNF-α DRUG, AND USE THEREOF
|
